NanoString Technologies, Inc. (NASDAQ:NSTG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 26, 2017, the Board appointed Dr. Mary Tedd Allen, 54, the Company’s current Vice President, Operations, as the Company’s Senior Vice President, Operations, effective May 1, 2017. Dr. Allen will replace Wayne Burns, who announced his departure on January 6, 2017 and whose last day as an employee will be April 30, 2017. The compensatory and other material terms of Dr. Allen’s employment arrangement with the Company have not changed in connection with her appointment.

Dr. Allen has more than 25 years of experience managing product development and manufacturing groups for both biotech and semiconductor applications. Dr. Allen has served as Vice President, Operations since early 2016, and she previously served as Vice President of Manufacturing since joining the Company in 2007. Prior to joining the Company, Dr. Allen served as the Director of Research and Programs at the Washington Technology Center, Washington state’s non-profit technology-based economic development enterprise, from February 2006 to February 2007. Before joining the Washington Technology Center, Dr. Allen was Vice President of the Advanced Manufacturing and Development group at Applied Biosystems, a publicly-traded biotechnology Company acquired by Invitrogen in November 2008 to form Life Technologies, from February 2002 to August 2005. She received a B.A. in Chemistry from Mount Holyoke College and a Ph.D. in Chemistry from the University of Rochester.

There are no family relationships between Dr. Allen and any director, executive officer or person nominated or chosen to become a director or executive officer of the Company. There are no transactions and no proposed transactions between Dr. Allen (or any member of her immediate family) and the Company (or any of its subsidiaries), and there is no arrangement or understanding between Dr. Allen and any other person or entity to which Dr. Allen was appointed as Senior Vice President, Operations.

About NanoString Technologies, Inc. (NASDAQ:NSTG)
NanoString Technologies, Inc. develops and manufactures intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. It markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology, and to clinical laboratories and medical centers for diagnostic use. Its molecular diagnostic product Prosigna Breast Cancer Assay provides an assessment of a patient’s risk of recurrence for breast cancer. NanoString Technologies, Inc. (NASDAQ:NSTG) Recent Trading Information
NanoString Technologies, Inc. (NASDAQ:NSTG) closed its last trading session up +0.08 at 17.48 with 69,004 shares trading hands.